Neurology Specific Literature Search   
 
[home][thesaurus]
    

Enter your terms
above and click
the 'Search' button.
Showing articles 0 to 50 of 618 Next >>

Filter Applied: efficacy (Click to remove)

Stroke Mechanism and Severity after Left Atrial Appendage Occlusion, Insights from the LAAOS III Randomized Clinical Trial
JAMA Neurol 83:76-82, Katsanos,A.H.,et al, 2026

Commonly Used Interventional Procedures for Non-Cancer Chronic Spine Pain: A Clinical Practice Guideline
BMJ 388:e079970, Busse,J.W.,et al, 2025

Left Atrial Appendage Closure After Ablation for Atrial Fibrillation
NEJM 392:1277-1287, Wazni,O.M.,et al, 2025

Collaboration on the Optimal Timing of Anticoagulation after Ischaemic Stroke and Atrial Fibrillation:A Systematic Review and Prospective Individual Participant Data Meta-Analysis of Randomised Controlled Trials (CATALYST)
Lancet 406:43-51, Dehbi,K-M.,et al, 2025

Patent Foramen Ovale Management for Secondary Stroke Prevention:State-of-the-Art Appraisal of Current Evidence
Stroke 55:236-247, Sposato,L.A.,et al, 2024

Five-Year Outcomes of PFO Closure or Antiplatelet Therapy for Cryptogenic Stroke
NEJM 384:970-971, , 2021

Use of Dual Antiplatelet Therapy Following Ischemic Stroke
Stroke 51:e78-e80, Dong, J.,et al, 2020


Neurol 93:975-977, Barghouthi, T.,et al, 2019

IV and mechanical thrombolysis for ischemic stroke secondary to cardiac myxoma
Neurol 93:975-977, Barghouthi, T., et al, 2019

Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation
NEJM 376:1627-1636, Calkins, H.,et al, 2017

Patent Foramen Ovale Closure or Anticoagulation Vs. Antiplatelets after Stroke
NEJM 377:1011-1021,1006,1093, Mas, J.L,et al, 2017

Patent Foramen Ovale Closure or Antiplatelet Therapy for Cryptogenic Stroke
NEJM 377:1033-1042,1006,1093, Sondergaard, L.,et al, 2017

Which Oral Anticoagulation for Atrial Fibrillation?
JAMA 315:2117-2118, The Medical Letter, 2016

Cost-Effectiveness of Oral Anticoagulants for Ischemic Stroke Prophylaxis Among Nonvalvular Atrial Fibrillation Patients
Stroke 47:1555-1561, Shah, A.,et al, 2016

Rates of Ischemic Stroke During Warfarin Treatment for Atrial Fibrillation
Stroke 46:1120-1122, Tung, J.M.,et al, 2015

Stroke Prevention in Atrial Fibrillation
JAMA 313:1950-1962, Lip, G.Y.H. & Lane, D.A., 2015

Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation
NEJM 373:823-833, Douketis,J.D.,et al, 2015

Comparison of the Efficacy and Safety of New Oral Anticoagulants with Warfarin in Patients with Atrial Fibrillation: A Meta-Analysis of Randomised Trials
Lancet 383:955-962,931, Ruff, C.T.,et al, 2014

Factor Xa Inhibitors vs Warfarin for Preventing Stroke and Thromboembolism in Patients with Atrial Fibrillation
JAMA 311:1150-1151, Bruins Slot, K.M.H. & Berge, E., 2014

Cerebrovascular Events in 21 105 Patients with Atrial Fibrillation Randomized to Edoxaban Versus Warfarin
Stroke 45:2372-2378, Giugliano, R.P.,et al, 2014

Closure of Patent Foramen Ovale versus Medical Therapy after Cryptogenic Stroke
NEJM 368:1092-1100,1152, Carroll, J.D.,et al, 2013

Percutaneous Closure of Patent Foramen Ovale in Cryptogenic Embolism
NEJM 368:1083-1091,1152, Meier, B.,et al, 2013

Faxtor Xa Inhibitors Versus Vitamin K Antagonists for Preventing Cerebral or Systemic Embolism in Patients with Atrial Fibrillation
Stroke 44:e165-e167, Bruins, K.M.H., & Berge, E., 2013

Left Atrial Catheter Ablation and Ischemic Stroke
Stroke 43:265-270, Haeusler, K.G.,et al, 2012

Using Dabigatran in Patients with Stroke A Practical Guide for Clinicians
Stroke 43:271-279, Alberts, M.J.,et al, 2012

Self-Monitoring of Oral Anticoagulation: Systematic Review and Meta-Analysis of Individual Patient Data
Lancet 379:322-34, Heneghan,C., 2012

Patent Foramen Ovale Closure and Medical Treatments for Secondary Stroke Prevention
Stroke 43:422-431, Kitsios,G.D.,et al, 2012

Dabigatran etexilate versus warfarin as the oral anticoagulant of choice? A review of clinical data
Pharmacol Ther 129:185-194, Terry, K.W.,et al, 2011

Apixaban in Atrial Fibrillation From Bleeding Cows to 21st Century Medicinal Chemistry
Stroke 42:2376-2378, Cucchiara, B.L.,et al, 2011

Rivaroxaban versus Warfarin in Nonvavular Atrial Fibrillation
NEJM 365:883-891, 952, Patel, M.R.,et al, 2011

Apixaban versus Warfarin in Patients with Atrial Fibrillation
NEJM 365:981-992,1052, Granger, C.B.,et al, 2011

Dronedarone in High-Risk Permanent Atrial Fibrillation
NEJM 365:2268-2276,2321, Connoly, S.J.,et al, 2011

Catheter Ablation for Atrial Fibrillation
NEJM 365:2296-2304, Wazni, O.,et al, 2011

Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
NEJM 362:402-415, 456, Cohen,J.A.,et al, 2010

Dabigatran Challenges Warfarins Superiority for Stroke Prevention in Atrial Fibrillation
Stroke 41:1307-1309, Schwartz,N.E. &Albers,G.W., 2010

Quality of Anticoagulation Control in Atrial Fibrillation
Lancet 376:935-937, Lane,D.A. &Lip,G.Y.H., 2010

Efficacy and Safety of Dabigatran Compared With Warfarin at Different Levels of International Normalised Ratio Control for Stroke Prevention in Atrial Fibrillation: An Analysis of the RE-LY Trial
Lancet 376:975-983, Wallentin,L.,et al, 2010

Study Design of the CLOSURE I Trial: A Prospective, Multicenter, Randomized, Controlled Trial to Evaluate the Safety and Efficacy of the STARFlex Septal Closure System Versus Best Medical Therapy in Patients With Stroke or TIA Due to Presumed Paradoxical Embolism Through a PFO
Stroke 41:2872-2883, Furlan,A.J.,et al, 2010

Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation
NEJM 360:2066-2078,2127, The ACTIVE Investigators, 2009

Recurrent Cerebral Ischemia in Medically Treated Patent Foramen Ovale: A Meta-Analysis
Neurol 73:89-97,84, Almekhlafi,M.A.,et al, 2009

Dabigatran Versus Warfarin in Patients with Atrial Fibrillation
NEJM 361:1139-1151, 1200, Connolly,S.,et al, 2009

Management of Stroke in Infants and Children: A Scientific Statement From a Special Writing Group of the American Heart Association Stroke Council and the Council on Cardiovascular Disease in the Young
Stroke 39:2644-2691, Roach,E.S.,et al., 2008

Secondary Stroke Prevention With Ximelagatran Versus Warfarin in Patients With Atrial Fibrillation: Pooled Analysis of SPORTIF III and V Clinical Trials
Stroke 38:874-880, Akins,P.T.,et al, 2007

Clopidogrel Plus Aspirin Versus Oral Anticoagulation for Atrial Fibrillation in the Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events (ACTIVE W): A Randomised Controlled Trial
Lancet 367:1903-1912,1877, The ACTIVE Writing Group on behalf of the ACTIVE Investigators, 2006

Ximelagatran vs Warfarin for Stroke Prevention in Patients with Nonvalvular Atrial Fibrillation
JAMA 293:690-698,736, SPORTIF Executive Steering Committee for the SPORTIF V Investigators, 2005

Patent Foramen Ovale Closure Devices
JAMA 294:366-369, Maisel,W.H.&Laskey,W.K., 2005

Patent Foramen Ovale in Young Adults with Unexplained Stroke
NEJM 353:2361-2372, Kizer,J.R. &Devereux,R.B., 2005

Does Transcatheter Closure of Patent Foramen Ovale Really "Shut the Door?"
Stroek 35:2140, Anzola,G.P.,et al, 2004

A Randomized Trial of Tenecteplase in Acute Central Retinal Artery Occlusion
NEJM 394:442-450, Ryan,S.J.,et al, 2026



Showing articles 0 to 50 of 618 Next >>